Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515031 | 0.91 | ALDH1A1 (0.57) | MAPTALDH1A1TSHRTDP1RAB9A | |
| SCHEMBL29612519 | 0.91 | ALDH1A1 (0.57) | MAPTALDH1A1TSHRTDP1RAB9A | |
| SCHEMBL29670495 | 0.88 | ALDH1A1 (0.62) | MAPTALDH1A1TSHRTDP1RAB9A | |
| SCHEMBL420259 | 0.88 | ALDH1A1 (0.62) | MAPTALDH1A1TSHRTDP1RAB9A | |
| SCHEMBL17378355 | 0.84 | KAT2B (0.49) | MAPTALDH1A1PKMKAT2BLMNA | |
| SCHEMBL1842548 | 0.84 | HCAR3 (0.52) | MAPTALDH1A1RAB9APKMKAT2B | |
| SCHEMBL9652783 | 0.83 | RAB9A (0.56) | MAPTALDH1A1TSHRTDP1RAB9A | |
| SCHEMBL2467753 | 0.83 | ALDH1A1 (0.56) | MAPTALDH1A1TSHRTDP1RAB9A | |
| SCHEMBL2144381 | 0.82 | KAT2B (0.48) | MAPTALDH1A1TDP1RAB9APKM | |
| SCHEMBL2144387 | 0.82 | KAT2B (0.48) | MAPTALDH1A1TDP1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| CN-119604506-A | 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof | 拜斯丽治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240425481-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-11981657-B2 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | EPIGENETIX, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023250156-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-20230120413-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INSTITUTE (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2396327-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010093425-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093425-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120413-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRD3, BRDT, BRD4 | MAPT 2018/4885ALDH1A1 1795/4885TSHR 3383/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | MAPT 36/4885ALDH1A1 2359/4885TSHR 1577/4885 |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | MAPT 402/4885ALDH1A1 1941/4885TSHR 879/4885 |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | MAPT 738/4885ALDH1A1 2598/4885TSHR 375/4885 |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | MAPT 738/4885ALDH1A1 2598/4885TSHR 375/4885 |
| US-11981657-B2 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | BRD3, BRDT, BRD4 | MAPT 2018/4885ALDH1A1 1795/4885TSHR 3383/4885 |
| US-20240425481-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRD3, BRDT, BRD4 | MAPT 2018/4885ALDH1A1 1795/4885TSHR 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.